M&A / Deals Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug BioPharma DiveIf consummated, the deal would hand Merck a treatment that could challenge Novartis fast-selling Scemblix.M&A / DealsHematologyRead full story pharminent March 25, 2026 (Last updated: March 25, 2026) BioPharma Dive If consummated, the deal would hand Merck a treatment that could challenge Novartis fast-selling Scemblix. M&A / DealsHematologyRead full story Post navigation Previous: Karyopharm myeloma drug yields mixed data in myelofibrosis trialNext: Sarepta sees early success with RNAi drugs from Arrowhead Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
